Payment overview · 2025
General Payments
$782.17
40 reported records · 15 companies
Healthcare provider profile · identity verified
David J Hoeft, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · OMAHA, NE · NPI 1215087218
Verified facts
What the public records show
CMS Open Payments records show David J Hoeft, M.D. received $782.17 in general payments during 2025 across 40 reported records.
Sumitomo Pharma America, Inc. accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $153.46 | 19.6% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $113.20 | 14.5% | 10 | 2025 |
| EnduroMed, LLC | Unresolved — no canonical attribution shown | $72.06 | 9.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $72.05 | 9.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.26 | 7.5% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $55.04 | 7.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.70 | 6.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $43.23 | 5.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $41.04 | 5.2% | 3 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $30.92 | 4.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.00 | 3.6% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $20.67 | 2.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.15 | 2.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.84 | 2.0% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $14.55 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $782.17 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $153.46 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $113.20 | 10 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $72.05 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $55.04 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $54.89 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $44.27 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $43.23 | 2 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $30.92 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $28.00 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 65 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
65 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 394 | 107 |
| Amlodipine Besylate | Amlodipine Besylate | 315 | 88 |
| Omeprazole | Omeprazole | 254 | 62 |
| Simvastatin | Simvastatin | 180 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 167 | 47 |
| Metformin Hcl | Metformin Hcl | 136 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 133 | 37 |
| Lisinopril | Lisinopril | 129 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 31 |
| Potassium Chloride | Potassium Chloride | 123 | 35 |
| Gabapentin | Gabapentin | 115 | 31 |
| Alprazolam | Alprazolam | 113 | 12 |
| Tramadol Hcl | Tramadol Hcl | 113 | 26 |
| Losartan Potassium | Losartan Potassium | 111 | 32 |
| Furosemide | Furosemide | 108 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 93 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 81 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 80 | 23 |
| Eliquis | Apixaban | 65 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 18 |
| Meloxicam | Meloxicam | 61 | 20 |
| Carvedilol | Carvedilol | 59 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 55 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | suppressed |
| Mirtazapine | Mirtazapine | 54 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 15 |
| Glimepiride | Glimepiride | 47 | 12 |
| Montelukast Sodium | Montelukast Sodium | 47 | 11 |
| Atenolol | Atenolol | 45 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 45 | 14 |
| Glipizide | Glipizide | 44 | suppressed |
| Clonazepam | Clonazepam | 43 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 41 | 12 |
| Trulicity | Dulaglutide | 41 | suppressed |
| Lorazepam | Lorazepam | 40 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 40 | suppressed |
| Torsemide | Torsemide | 40 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 39 | suppressed |
| Jardiance | Empagliflozin | 37 | suppressed |
| Allopurinol | Allopurinol | 36 | suppressed |
| Prednisone | Prednisone | 36 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 34 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 15 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Nexium | Esomeprazole Magnesium | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $782.17 · 40 records | Sumitomo Pharma America, Inc. | ABRYSVO, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FARXIGA, FFRct, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, INSPIRE, MAVYRET, MOUNJARO, NURTEC ODT, Ohtuvayre, Ozempic, PREVNAR 20, Rybelsus, VOQUEZNA, VRAYLAR, VYNDAMAX, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error